We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Recommends Inlyta for Kidney Cancer, Turns Down Provenge for Prostate Cancer
NICE Recommends Inlyta for Kidney Cancer, Turns Down Provenge for Prostate Cancer
The UK’s healthcare cost watchdog issued a mixed bag of recommendations Wednesday, supporting Pfizer’s Inlyta as a second-line treatment for advanced kidney cancer while nixing Dendreon’s Provenge for asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer.